Business Wire

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement

29.4.2026 14:00:00 EEST | Business Wire | Press release

Share

Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/

Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities.

“Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide a common settlement layer across all of them.”

Newly supported blockchains

Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities:

  • Arc: An open Layer-1 blockchain created by Circle, purpose-built to unite programmable money and onchain innovation with real-world economic activity.
  • Base: A high-performance blockchain enabling fast, low-cost settlement for stablecoins, onchain assets and agentic commerce. Powered by Coinbase.
  • Canton: Built with configurable privacy for regulated capital markets, enabling compliant settlement for institutional use cases.
  • Polygon: A leading blockchain payments solution that enables fast, low-cost transactions, delivering seamless, high-throughput infrastructure for global payments and digital commerce.
  • Tempo: Focused on faster, private, and more efficient movement of stablecoin liquidity and settlement flows.

With these additions, Visa now supports nine blockchains across its global stablecoin settlement pilot program, giving partners more choice while building on existing support for Avalanche, Ethereum, Solana, and Stellar.

From experimentation to multi-chain reality

Over the past year, stablecoins have evolved from a promising innovation to a practical way to move money globally, and Visa’s settlement pilots are helping partners streamline operations.

This builds on years of live pilots and regional rollouts across LAC, Europe, AP and CEMEA, as well as the recent expansion of USDC settlement to U.S. banks and 130+ stablecoin-linked card programs in more than 50 countries. The move to nine supported blockchains mirrors a broader trend: liquidity and activity now span a diverse, multi-chain ecosystem, and settlement infrastructure is evolving to match to provide more choice.

Visa is building toward a future where interoperability is essential. Supporting multiple blockchains gives partners more choice in how they access liquidity across ecosystems and adapt as the landscape changes, while Visa eases some of the underlying complexity so institutions can use stablecoins through a trusted, global network.

Continued momentum

The growth to a $7B run rate underscores increasing confidence in blockchain infrastructure from financial institutions, fintechs, and payment providers. Stablecoin settlement over blockchain infrastructure is becoming a viable complement to traditional settlement rails.

As adoption continues, Visa remains focused on bridging traditional finance and blockchain-based systems - bringing the same standards of reliability, security, and scale to both.

Partner perspectives

“Arc is designed to provide the performance, predictability, and reliable access to liquidity needed to support real-time settlement at a global scale. Our work with Visa reflects growing demand for stablecoins like USDC and blockchain infrastructure that can settle today’s payment flows instantly while enabling the next era of programmable commerce and agent-driven economic activity.” Nikhil Chandhok, Chief Product and Technology Officer, Circle.

“Our goal with Base has always been to make onchain the new standard. Visa’s expansion is a pivotal step in making stablecoin payments a daily reality for billions of people, enabling a faster, cheaper, and more useful financial system for everyone,” said Jesse Pollak, Founder of Base.

“Canton was designed to meet demanding requirements of regulated institutions, and Visa’s stablecoin settlement platform provides a bridge that lets them explore onchain settlement while staying aligned with their compliance requirements,” said Eric Saraniecki, Head of Network Strategy at Digital Asset, co-founder of the Canton Network.

“Visa adding Polygon signals that stablecoins are moving into real world payments at scale. By combining Visa’s global reach with Polygon’s fast, low-cost infrastructure, we are making stablecoin settlement more practical, reliable, and accessible for partners around the world,” said Marc Boiron, CEO, Polygon Labs.

“Tempo is focused on real-time stablecoin settlement, and Visa’s participation as both a validator and settlement partner helps bring always-on, programmable payments closer to the mainstream,” said Ani Narayan, GTM, Tempo.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260429143049/en/

Contacts

Media Contacts
Jackie Dresch - jdresch@visa.com
Conor Febos cfebos@visa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye